Peritumoral portal enhancement during transarterial chemoembolization: a potential prognostic factor for patients with hepatocellular carcinoma

Sofi Sennefelt Nyman1, Angeliki Dimopoulou Creusen1, Ulf Johnsson1, Fredrik Rorsman2, Johan Vessby2 and Charlotte Ebeling Barbier1

Abstract

Background: Tumor response and survival varies in patients treated with transarterial chemoembolization (TACE) for intermediate stage hepatocellular carcinoma (HCC) and may be associated with several factors.

Purpose: To evaluate safety and efficacy of TACE in patients with intermediate stage HCC and to identify factors related to tumor response and survival.

Material and Methods: Consecutive patients with HCC treated with TACE between September 2008 and September 2018 were retrospectively reviewed.

Results: In 87 patients (71 men; mean age = 68 ± 9 years), 327 TACE treatments were performed (mean = 3/patient; range = 1–12). Mean and median overall survival were 32 and 19 months, respectively. Survival rates at 30 days, one, three, and five years were 99%, 71%, 19%, and 8%, respectively. Objective response (OR) was seen in 84% and disease control (DC) was seen in 92% of the patients. Patients in whom peritumoral portal lipiodol enhancement (PPLE) was seen during TACE had better OR (97 vs. 73%; \( P = 0.007 \)) and DC (100 vs. 85%; \( P = 0.024 \)), and a reduced risk of death (hazard ratio [HR] = 0.52; 95% confidence interval = 0.32–0.86) compared to those without PPLE. Severe adverse events were rare (15%) and occurred more often in patients with a larger tumor size.

Conclusions: TACE was effective and safe in patients with intermediate stage HCC. Patients with PPLE during TACE had better tumor response and longer survival than those without PPLE. Severe adverse events occurred more often in patients with larger tumors.

Keywords

Hepatocellular carcinoma, transarterial chemoembolization, liver, angiography, abdomen/GI, interventional

Introduction

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death in the world, representing the seventh most common cancer (1). The incidence of HCC is expected to increase (2). HCC occurs mainly in patients with chronic liver diseases, such as cirrhosis caused by viral hepatitis, alcohol fatty liver disease (AFLD), and non-alcoholic fatty liver disease (NAFLD) (3–5).

The recommended treatment of intermediate stage HCC is transarterial chemoembolization (TACE), conventional or with drug eluting beads (DEB-TACE) (6), since it prolongs survival (7). No major difference in efficacy and safety has been found between conventional and DEB-TACE (8,9).

Local variations between treatment centers occur concerning the conventional TACE procedure. The addition of an embolic agent at the end of the procedure has not been proved to influence overall survival or tumor response (10,11).

1Department of Surgical Sciences, Section of Radiology, Uppsala University, Uppsala, Sweden
2Department of Medical Sciences, Section of Gastroenterology and Hepatology, Uppsala University, Uppsala, Sweden

Corresponding author: Sofi Sennefelt Nyman, Intervention Radiology, BFC, Akademiska sjukhuset, 751 85 Uppsala, Sweden.
Email: sofi.nyman@hotmail.com
Adverse events (AE) related to TACE are usually transient and treatable (12). Severe adverse events (SAE) are associated with advanced liver disease (Child-Pugh B and C), a central tumor localization, and a large tumor volume (13).

The efficacy of TACE varies concerning tumor response and survival (8,13–17) and may be associated with several factors such as tumor size, Child Pugh class, Barcelona clinic liver cancer (BCLC) stage, tumoral enhancement or peritumoral portal lipiodol enhancement (PPLE) during TACE, serum C-reactive protein (CRP), serum albumin, and alpha-fetoprotein (AFP) levels (18–25).

The aim of the present study was to evaluate the safety and efficacy of TACE and to identify factors related to tumor response and survival in patients with intermediate stage HCC. A hypothesis was that arterial tumor enhancement on pre-TACE CT, tumor enhancement during TACE, and PPLE would reflect tumor response and survival.

**Material and Methods**

**Patient data**

All patients with HCC who had their first TACE treatment at our University Hospital between September 2008 and January 2018 were identified. A retrospective review was performed after approval from the regional research ethics and review board. Informed consent was sent to patients who were still alive (n = 16) for their signature. Data concerning AEs, biomarkers, previous treatments, presence and etiology of cirrhosis, clinical ascites, body mass index (BMI), and date of death were obtained from medical records (SSN). The diagnosis of cirrhosis was determined according to clinical routine based on biopsy, imaging, clinical, anamnestic findings, and laboratory parameters.

The picture archiving system and the radiology information system were reviewed concerning the TACE procedures, magnetic resonance imaging (MRI), and computed tomography (CT) examinations (SSN, CEB).

The Common Terminology Criteria for Adverse Events (CTCAE) version 4 (26) was used to categorize AEs occurring within 30 days. Post-embolization syndrome (PES) was defined as one or several of the following symptoms: pain; fever; nausea; and vomiting. The cause of death was retrieved from the national cause of death register at the national board of health and welfare.

**TACE procedure**

The TACE procedure was performed by an interventional radiologist (CEB, ADC, or UJ) in a standardized manner. To confirm patent portal vein circulation before treatment, either ultrasound or prolonged angiographic imaging was used. The femoral artery was punctured under local anesthesia. Selective angiography of the superior mesenteric artery and the coeliac trunk was performed in order to determine the arterial anatomy, detect accessory tumor feeders, and arteriportal shunts. The latter was considered a contraindication to TACE.

The right or left hepatic artery feeding the tumor or tumors was selectively catheterized and embolized with an emulsion of 50 mg of doxorubicin (Adriamycin; Pfizer Inc., New York, NY, USA) mixed with 13 ml of Lipiodol Ultra Fluid (Guerbet, Aulnay-sous-Bois, France) until the total amount was given or until arterial stasis was achieved. A lobar catheter position was chosen to attain treatment to potential accessory tumors. No embolic material was added since frequent repeated treatments were planned. If there were tumors in both liver lobes, the treatment sessions were altered between the lobes, beginning with the lobe with the largest tumor burden. If the treatment was tolerated by the patient, it was repeated every 6–8 weeks and an evaluation with CT or MRI was performed after treatment 3 or 5. If viability was still seen, treatments were pursued with the same intervals until complete response or progressive disease as long as no major adverse effects occurred.

**Tumor evaluation**

To evaluate tumor enhancement a region of interest was drawn on the slice where the tumor appeared largest and most enhanced on arterial phase contrast-enhanced CT before TACE. Tumor lipiodol enhancement was graded from no enhancement to dense enhancement (0–2) on TACE images. PPLE was defined as lipiodol persisting in peritumoral portal vessels during TACE (example displayed in Fig. 1).

To evaluate tumor response, MRI and CT images that had been obtained as close as possible before TACE (mean = 10 weeks) were compared to the images obtained as close as possible after the last TACE treatment (mean = 9 weeks). Measurements were performed on the three largest tumors (SSN) in the treated lobe/lobes, according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) (27), considering a decrease of viable tumor diameter \( \leq 30\% \) as response and an increase \( \geq 20\% \), or the appearance of a new lesion in the treated lobe, or of extrahepatic tumor, as progress. In patients where there was no post-TACE CT or MRI, assessments were performed on ultrasound (n = 3).

Thus, the accumulative response was evaluated for each patient after all TACE treatments had been performed. Objective response (OR) was defined as complete remission (CR) plus partial response (PR). Disease control (DC) was defined as OR plus stable disease (SD).

**Statistical analysis**

SPSS Statistics version 23 (IBM Corp., Armonk, NY, UA) was used for statistical analyses. The T-test with Levene’s test for equal variances was used to compare means between groups to evaluate tumor response, treatment effect on biomarkers, and to compare the severity of AEs and the effect on biomarkers. Continuous parameters were analyzed.
using Spearman rank correlation and categorical parameters were analyzed using Pearson chi-square test. The Cox proportional hazards model and the Kaplan–Meier method were used to estimate survival, when the observed variable was categorical, starting from the day of the first TACE treatment. Simple and multiple regression analysis was used to analyze factors associated to survival and tumor response. The Mann–Whitney test was used to compare the groups with and without PPLE. The significance level was set at $P < 0.05$ in all analyses.

**Results**

**Demographics**

Between September 2008 and September 2018, 89 consecutive patients with HCC were treated with TACE. Two patients were excluded from the study: one due to emigration and the other because no written informed consent was received. The remaining 87 patients constituted the study population of the present study. The mean follow-up time was 26 months (range = 5 days–126 months). A total of 327 TACE treatments were performed (median 3/patient; range = 1–12).

In 5 of 327 treatments where lipiodol and doxorubicin were not available at the pharmacy, DC Beads (Terumo Corp., Tokyo, Japan) filled with 150 mg of doxorubicin was used. The mean administrated doses of doxorubicin at the first five TACE treatments were 49 mg, 43 mg, 40 mg, 22 mg, and 12 mg, respectively, and the mean total dose was $160 \pm 109$ mg.

Baseline characteristics are presented in Table 1.

**Tumor response**

There were no post-TACE images in 14 of the patients. Thus, 73 patients were included in the mRECIST
assessments (Table 2). OR was seen in 84% (n = 61/73) and DC was seen in 92% (n = 67/73) of patients.

OR or DC was more frequent in patients in whom PPLE was achieved during any of the TACE procedures compared to in those in whom PPLE was never achieved (97 vs. 73%; \( P = 0.007 \) and 100 vs. 85%; \( P = 0.024 \), respectively). There was also a positive correlation between the number of times that PPLE occurred in a patient (including the first five TACE treatments) and the occurrence of OR (n = 31/61 vs. 1/12; \( P = 0.012 \); correlation coefficient = 0.29) or DC (n = 32/67 vs. 0/6; \( P = 0.031 \); correlation coefficient = 0.25). Objective response was more frequently obtained in patients with (n = 21/21) than patients without (n = 39/51) PPLE during first TACE (\( P = 0.015 \)). In the simple and multiple regression analyses, PPLE was associated with OR (\( P = 0.009 \) and 0.049, respectively). Factors analyzed in the regression analysis are displayed in Table 3. There was no difference between the groups with or without PPLE regarding age, sex, size of the largest tumor, whether the tumors were uni- or bilobar, Child Pugh class, BCLC stage, AFP < 400 μg/L, CRP < 10 mg/L, or albumin <35 g/L. In 68 patients, where image quality allowed quantification of the necrotic part of the largest tumor, the necrotic part was greater in patients with PPLE (n = 30) compared to those without PPLE (n = 38) (mean = 85% and 67%, respectively; \( P = 0.026 \)).

There was no association between tumor response and the arterial enhancement on pre-TACE CT, the occurrence of tumor lipiodol enhancement during TACE, the total dose of doxorubicin, tumor size (>8 cm in 12/73 patients), type of cirrhosis, serum levels of albumin, CRP, and AFP before the first treatment.

**Survival**

Mean overall survival was 32 months (95% confidence interval [CI] = 24–40) and median 19 months (range = 0–126 months), evaluated in 83 of the patients (excluding four patients who had a liver transplantation after TACE). Survival rates at 30 days, one, three, and five years were 98%, 71%, 20%, and 8%, respectively.

### Table 1. Baseline characteristics of 87 patients with HCC treated with TACE.

| Characteristics                  | Value                      |
|----------------------------------|----------------------------|
| Sex (F)                          | 16 (18)                    |
| Age (years)                      | 68 ± 9 (45–88)             |
| BMI                              | 28 (17–42)                 |
| Clinical liver cirrhosis         | 68 (78)                    |
| Viral hepatitis\( ^{a} \)        | 13 (15)                    |
| Alcoholic fatty liver disease    | 12 (14)                    |
| Alcoholic fatty liver disease + viral hepatitis\( ^{b} \) | 20 (23) |
| Non-alcoholic fatty liver disease| 6 (7)                      |
| Others\( ^{\dagger} \)           | 17 (19)                    |
| No clinical liver cirrhosis      | 9 (10)                     |
| HCC diagnosed with biopsy, AFP + imaging, no information | 6, 2, 1 |
| No information on liver cirrhosis| 10 (12)                    |
| HCC diagnosed with biopsy, AFP + imaging, no information | 3, 4, 3 |
| BCLC (A (%)/B (%)/C (%))         | 29 (33)/49 (56)/9 (11)     |
| Child Pugh (A (%)/B (%))         | 77 (88)/10 (12)            |
| Systemic chemotherapy and/or radiation pre-TACE | 7 (8) |
| Surgical resection and/or ablation pre-TACE | 13 (15) |
| Number of tumors                 | 3.4 (1–50)                 |
| 1                                | 36 (41)                    |
| 2                                | 19 (22)                    |
| >2                               | 31 (37)                    |
| Bilobar                          | 30 (35)                    |
| Largest tumor diameter (cm)      | 6.2 (1.6–19)               |
| Transplanted after TACE          | 4 (5)                      |
| AFP\( ^{c} \)                    | 941 (2–14,480)             |

Values are given as n (%), mean ± SD (range), or mean (range) unless otherwise indicated.

\( ^{a} \)Others include: alcoholic fatty liver disease + non-alcoholic fatty liver disease (n = 3); hemochromatosis (n = 1); porphyria (n = 2); hemochromatosis + alcohol fatty liver disease + viral hepatitis (n = 1); hemochromatosis + alcoholic fatty liver disease + non-alcoholic fatty liver disease (n = 1); and unclear etiology (n = 9).

\( ^{\dagger} \)Only available in 81 patients.

AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization.

### Table 2. Accumulative tumor response, for the entire study period, using mRECIST in 73 patients with HCC who had TACE.

| mRECIST              | n total = 73 | OR = 61(84) | DC = 67(92) |
|----------------------|--------------|-------------|-------------|
| Complete response, n (%) | 36 (49)     |             |             |
| Partial response, n (%)   | 25 (34)    |             |             |
| Stable disease, n (%)     | 6 (8)       |             |             |
| Progressive disease (%)   | 6 (8)       |             |             |

Values are given as n (%) unless otherwise indicated.

DC, disease control; HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; OR, objective response; TACE, transarterial chemoembolization.
At the time of the analysis, 84% (n = 70/83) of the patients were deceased. In 83% (n = 57/69) of these patients, the cause of death was related to cirrhosis and HCC.

Patients with PPLE survived longer than those without PPLE (mean = 37 months; 95% CI = 28–47 and 28 months; 95% CI = 17–38, respectively; P = 0.014)(Fig. 2). Hazard ratios for death are displayed in Fig. 3. Survival >24 months was associated with PPLE in both the simple and the multiple regression analyses (P = 0.012 and 0.017, respectively). Factors analyzed in the regression analysis are displayed in Table 4. Child Pugh class, the BCLC classification, or the etiology of the patient’s liver

---

**Table 3.** Simple and multiple regression analysis of factors associated with OR in 73 patients with HCC treated with TACE (patients were divided into two groups: responders and non-responders to TACE).

| Parameters                             | Responders* | Non-responders* | P value simple analysis | P value multiple analysis |
|----------------------------------------|-------------|-----------------|-------------------------|--------------------------|
| Mean age (years)                       | 67          | 68              | 0.630                   | 0.535                    |
| Sex (F)                                | 12/61 (20)  | 1/12 (8)        | 0.330                   | 0.177                    |
| PPLE                                   | 31/61 (51)  | 1/12 (8)        | 0.009                   | 0.049                    |
| Largest tumor >8 cm                    | 10/61 (16)  | 2/12 (17)       | 0.989                   | 0.381                    |
| Single tumors compared to multiple     | 25/61 (41)  | 2/12 (17)       | 0.089                   | 0.196                    |
| Unilobar tumors compared to bilobar    | 42/61 (69)  | 6/12 (50)       | 0.474                   | 0.797                    |
| AFP >400 μg/L                          | 53/56 (95)  | 9/11 (82)       | 0.182                   | 0.171                    |
| Albumin <35 g/L                        | 33/59 (56)  | 9/12 (75)       | 0.140                   | 0.346                    |
| CRP < 10 mg/L                          | 42/56 (75)  | 9/11 (82)       | 0.586                   | 0.400                    |

Values are given as n (%) unless otherwise indicated.

*Responders = OR according to mRECIST.

AFP, alpha-fetoprotein; CRP, C-reactive protein; HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; OR, objective response; PPLE, peritumoral portal lipiodol enhancement; TACE, transarterial chemoembolization.

---

**Fig. 2.** Kaplan–Meier graph displaying survival in 83 patients with HCC with or without PPLE during TACE. HCC, hepatocellular carcinoma; PPLE, peritumoral portal lipiodol enhancement; TACE, transarterial chemoembolization.
cirrhosis did not influence the risk of death. There was no association between survival and the total amount of doxorubicin that a patient received.

The size of the largest tumor in these 83 patients was >5 cm in 46, >8 cm in 18, and >10 cm in 13 patients.

**Adverse events and biomarkers**

Of the patients, 61%–70% had no perioperative AEs during the first five treatments (Table 5) and in 42% (n = 137/327) of the TACE treatments no postoperative AEs occurred. The frequency of post-TACE PES is presented in Table 6.

Mild postoperative AEs (CTCAE 1–2) occurred after 43% of the treatments (n = 142/327) and SAEs (CTCAE 3–5) occurred after 15% (n = 48/327) of the treatments (detailed information is presented in Supplementary Table 1). The risk of experiencing a SAE increased with increasing size of the largest tumor (P = 0.003). Patients with life-threatening AEs within 30 days (CTCAE grades 4 and 5) are further described in Supplementary Table 2.

Alanine transaminase, aspartate aminotransferase, bilirubin, and international normalized ratio (INR) increased slightly after each TACE compared to levels before first TACE (P < 0.05). All but bilirubin were normalized when controlled after the last treatment. This was not considered an AE. However, there was a positive association between these biomarkers after TACE and the CTCAE grade after first treatment (P = 0.017, 0.010, 0.033, and 0.028, respectively).

---

**Fig. 3.** Forest plot displaying hazard ratios for death in main analysis parameters in patients with HCC treated with TACE. Objective response and disease control were calculated according to the mRECIST criteria for tumor response. CRP, C-reactive protein; HCC, hepatocellular carcinoma; mRECIST, modified Response and Evaluation Criteria in Solid Tumors; PPLE, peritumoral portal lipiodol enhancement; TACE, transarterial chemoembolization.

**Table 4.** Simple and multiple regression analysis of factors associated with survival in 82 patients with HCC treated with TACE (patients were divided into two groups: survival 24 months or shorter, and survival longer than 24 months).

| Parameters | Survival ≤24 months | Survival >24 months | P value simple analysis | P value multiple analysis |
|------------|---------------------|----------------------|------------------------|-------------------------|
| Mean age (years) | 68 | 68 | 0.740 | 0.571 |
| Sex (F) | 12/51 (24) | 4/32 (13) | 0.511 | 0.595 |
| PPLE | 15/51 (29) | 17/32 (53) | 0.012 | 0.017 |
| First PPLE treatment* | 10/51 (20) | 10/32 (31) | 0.056 | - |
| Largest tumor >8 cm | 11/51 (22) | 7/32 (22) | 0.882 | 0.188 |
| Single tumors compared to multiple | 24/51 (47) | 11/32 (34) | 0.938 | 0.286 |
| Unilobar tumors compared to bilobar | 33/51 (65) | 23/32 (72) | 0.263 | 0.172 |
| AFP >400 μg/L | 40/49 (82) | 26/28 (93) | 0.233 | 0.195 |
| Albumin <35 g/L | 35/50 (70) | 14/31 (45) | 0.250 | 0.783 |
| CRP <10 mg/L | 33/50 (66) | 22/27 (81) | 0.089 | 0.084 |

Values are given as n (%) unless otherwise indicated.

*First PPLE treatment was not included in the multivariate analysis.

AFP, alpha-fetoprotein; CRP, C-reactive protein; HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; OR, objective response; PPLE, peritumoral portal lipiodol enhancement; TACE, transarterial chemoembolization.
There was good tumor response to TACE in the present study (OR = 84%, DC = 92%), consistent with other cohorts (OR = 54%–90%, DC = 85%–94%) (8,14,16). Overall mean and median survival were in the higher range (32 vs. 19 months) compared to other reports (mean = 23–31 months; median = 16–19 months) (13,15,17). Survival at one, three, and five years was consistent with other cohorts (i.e. 71%, 19%, and 8%, respectively, compared to survival at one, three, and five years of 70%, 40%, and 32%, respectively in a large meta-analysis (13) survival at one and three years of 46% and 8% in another (28)), indicating that TACE improves short-term survival, but does not necessarily influence long-term survival. The three- and five-year survival rates in the present study are limited by the mean follow-up time being only 26 months.

In the present study, the risk of death was reduced by half in patients with PPLE during any of the TACE treatments, whereas PPLE during the first TACE was not associated to survival (P = 0.056). This might suggest that a patient well enough to receive several treatments will have an increased chance of PPLE. However, our observation that PPLE during any of the TACE treatments reduced the risk of death confirms that not obtaining PPLE during first TACE must not indicate a bad prognosis. Thus, not having obtained PPLE during first TACE should not discourage from further TACE treatments. Perhaps some tumors need more than one treatment before the emulsion fills up the tumor and reaches the portal vessels. Therefore, having obtained PPLE during TACE might be considered a predictor of increased tumor response and survival compared to not having obtained PPLE. To the best of our knowledge, an association between PPLE and survival has not been reported before.

Our observation that PPLE during first TACE and during any TACE were independently positively correlated to tumor response supports the results of previous studies where the local recurrence rate of HCC is lower in patients with intense PPLE (18,29). It has been suggested that lipiodol would more easily pass through a moderately than a poorly differentiated tumor and thereby provide a greater ischemic effect, since there is a more complete outflow tract (30). This might be supported by the observation in one of our patients, displayed in Fig. 1. Therefore, PPLE could indicate the extent to which the tumor has been permeated with the lipiodol emulsion and, thus, exposed to the drug. Furthermore, a correlation between PPLE intensity and the extent of histopathological necrosis has been described (31), which may provide a pathophysiological explanation to the positive association between PPLE and tumor response and survival in the present study. However, a potential association between tumor differentiation and PPLE remains to be explored.

In a retrospective study of 105 patients, who received TACE as a bridge to transplantation, intense tumor enhancement during TACE was positively correlated to tumor response (19). In the present study, no such association was found. This might be explained by the fact that the tumors in the present study were generally larger with a larger distribution volume for the lipiodol and a larger area of tumor necrosis diluting the enhancement and making it less intense. In some studies, a correlation has been observed between a larger tumor size and a poorer

Table 5. Adverse events in patients with HCC during TACE treatment, observed at the interventional radiology department.*

| During TACE | TACE 1 (n = 85) | TACE 2 (n = 68) | TACE 3 (n = 57) | TACE 4 (n = 40) | TACE 5 (n = 25) |
|-------------|----------------|----------------|----------------|----------------|----------------|
| No complication | 52 (61) | 46 (68) | 39 (68) | 28 (70) | 17 (68) |
| Nausea/Pain | 28 (33) | 22 (32) | 17 (30) | 12 (30) | 8 (32) |
| Hypotension | 6 (7) | 0 | 2 (4) | 2 (5) | 0 |
| Bleeding/Hematoma | 4 (5) | 0 | 0 | 0 | 0 |

Values are given as n (%).
*First five treatments observed. Patients could have more than one complication.

HCC, hepatocellular carcinoma; PES, post-embolization syndrome; TACE, transarterial chemoembolization.

Table 6. Patients with HCC experiencing PES* after TACE.

| TACE treatment | Post-TACE PES |
|---------------|--------------|
| TACE 1        | 56/87 (65)   |
| TACE 2        | 43/68 (64)   |
| TACE 3        | 29/57 (51)   |
| TACE 4        | 18/40 (45)   |
| TACE 5        | 12/25 (48)   |

Values are given as n (%).
*Defined as one or several of the following symptoms: pain; fever; nausea; and vomiting.

HCC, hepatocellular carcinoma; PES, post-embolization syndrome; TACE, transarterial chemoembolization.
tumor response and survival (20,23,25,32,33), whereas no such correlation has been found in other studies (34,35). Even though there was a significant variation of tumor size in the present study, with 22% (n = 18/82) of the tumors being >8 cm in survival calculations and 16% (n = 12/73) in the tumor response calculations, there were no associations between tumor size and response or survival. This might partly be explained by the fact that the studies reporting a correlation between tumor size and outcome were performed in cohorts with a generally poorer liver status than our cohort. Thus, the decision to perform TACE should not exclusively be determined by the size of the tumor. However, increased attention to AE may be needed since an association was observed between SAE and a large tumor size (P = 0.003).

Elevated levels of CRP (21) and AFP (22), and decreased levels of albumin (25) are all predictors of poor outcome, which is confirmed by the results of the present study.

Lower Child Pugh class and BCLC stage before first treatment have been found to positively affect survival rates (23,24). This was not found in our cohort, perhaps due to a rather homogenic study population (9/87 BCLC C and 10/87 child Pugh B).

Only 2% of the TACE treatments (n = 7/327) entailed life-threatening AEs. Some of these could have been avoided: the symptoms of a myocardial infarction were misinterpreted as PES in one patient; TACE was performed despite imaging signs of a liver abscess in another; and in a patient with unrecognized active alcohol abuse. The increase in liver enzymes, bilirubin, and INR after TACE, in the present study, was not considered an AE since a transient elevation is expected (13).

The present study has some limitations. It was limited by its retrospective design and by the fact that the follow-up time was short in some patients. The study population is rather homogenic with most of the patients having a well-preserved liver function. When assessing tumor response and AEs, there is room for subjectivity by the interpreter. In order to minimize this, categorization was performed using validated instruments such as mRECIST and CTCAE.

In conclusion, TACE was effective and safe in patients with intermediate stage HCC and relatively preserved liver function. Patients with PPLE during TACE had better tumor response and longer survival than those without PPLE. Tumor size or tumor lipiodol enhancement during TACE was not associated to tumor response or survival. However, SAEs occurred more often in patients with larger tumors compared to those with smaller tumors.

**Declaration of conflicting interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) received no financial support for the research, authorship and/or publication of this article.

**ORCID iD**
Sofi Sennefelt Nyman https://orcid.org/0000-0002-8911-2927
Johan Vessby https://orcid.org/0000-0003-1832-6386
Charlotte Ebeling Barbier https://orcid.org/0000-0003-4855-5841

**Supplemental material**
Supplemental material for this article is available online.

**References**
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156:477–491.e471.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–1273.e1261.
4. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323–331.
5. Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019;16:411–428.
6. European Association for the Study of the Liver. EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.
7. Katsanos K, Kitrou P, Spiliopoulos S, et al. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. PLoS One 2017;12:e0184597.
8. Gofrieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014;111:255–264.
9. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52.
10. Okusaka T, Kasugai H, Shioyama Y, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2009;51:1030–1036.
11. Kirchhoff TD, Rudolph KL, Layer G, et al. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol 2006;32:201–207.
12. Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94:1747–1752.
13. Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016;64:106–116.
14. Gillmore R, Stuart S, Kirkwood A, et al. EASL And mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309–1316.
15. Gomes AS, Monteleone PA, Sayre JW, et al. Comparison of triple-drug transcatheter arterial chemoembolization (TACE) with single-drug TACE using doxorubicin-eluting beads: long-term survival in 313 patients. Am J Roentgenol 2017;209:722–732.
16. Song MJ, Chun HJ, Kim HY, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012;57:1244–1250.
17. Soydal C, Arslan MF, Kucuk ON, et al. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona clinic liver cancer stage BC hepatocellular cancer patients. Nucl Med Commun 2016;37:646–649.
18. Miyayama S, Matsui O, Yamashiro M, et al. Ultrasound-selective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007;18:365–376.
19. Kwan SW, Fidelman N, Ma E, et al. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012;18:727–736.
20. Hu HT, Kim JH, Lee L-S, et al. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol 2011;22:917–923.
21. Shin JH, Kim CJ, Jeon EJ, et al. Overexpression of C-reactive protein as a poor prognostic marker of resectable hepatocellular carcinomas. J Pathol Transl Med 2015:49:105–111.
22. Ichikawa T, Machida N, Sasaki H, et al. Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients Who underwent transarterial chemoembolization. Oncology 2016;91:317–330.
23. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994;19:1115–1123.
24. Vogeler M, Mohr I, Pfeiffenberger J, et al. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146(4):1–18.
25. O’Suilleabhain CB, Poon RT, Yong JL, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003;90:325–331.
26. U.S. Department of Health and Human Services. Common terminology criteria for adverse events, version 4.0. Bethesda, MD: National Institutes of Health. 2010.
27. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.
28. Lobo L, Yakoub D, Picado O, et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 2016;39:1580–1588.
29. Bannangkoon K, Hongsaokul K, Tubatwee T, et al. Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization. Clin Mol Hepatol 2019;25:74–79.
30. Yoshimitsu K. Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma: perspective from multistep hepatocarcinogenesis. Hepat Med 2014;6:89.
31. Miyayama S, Mitsui T, Zen Y, et al. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2009;39:374–381.
32. Golferi R, Renzulli M, Mosconi C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol 2013;24:509–517.
33. Paul SB, Gamanagatti S, Sreenivas V, et al. Trans-arterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma: experience from a tertiary care centre in India. Indian J Radiol Imaging 2011;21:113–120.
34. Herber S, Biesterfeld S, Franz U, et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008;31:768–777.
35. Katayama K, Imai T, Abe Y, et al. Number of nodules but not size of hepatocellular carcinoma can predict refractoriness to transarterial chemoembolization and poor prognosis. J Clin Med Res 2018;10:765. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf